OVID
Income statement / Annual
Last year (2023), Ovid Therapeutics Inc.'s total revenue was $391,695.00,
a decrease of 73.93% from the previous year.
In 2023, Ovid Therapeutics Inc.'s net income was -$52.34 M.
See Ovid Therapeutics Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$391,695.00
|
$1.50 M
|
$208.38 M
|
$12.62 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$1.60 M |
$1.38 M |
$0.00 |
$0.00 |
$255,000.00 |
$141,733.00 |
$80,310.00 |
$56,512.00 |
$11,778.00 |
$0.00 |
| Gross Profit |
-$1.20 M |
$121,142.00 |
$208.38 M |
$12.62 M |
-$255,000.00 |
-$141,733.00 |
-$80,310.00 |
-$56,512.00 |
-$11,778.00 |
$0.00 |
| Gross Profit Ratio |
-3.08 |
0.08 |
1 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$28.59 M
|
$24.62 M
|
$46.94 M
|
$63.42 M
|
$42.16 M
|
$33.79 M
|
$49.97 M
|
$9.59 M
|
$6.61 M
|
$105,375.00
|
| General & Administrative
Expenses |
$31.09 M
|
$32.43 M
|
$37.23 M
|
$30.63 M
|
$19.25 M
|
$19.14 M
|
$15.04 M
|
$12.95 M
|
$6.58 M
|
$0.00
|
| Selling & Marketing
Expenses |
$726.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$31.09 M
|
$32.43 M
|
$37.23 M
|
$30.63 M
|
$19.25 M
|
$19.14 M
|
$15.04 M
|
$12.95 M
|
$6.58 M
|
$341,517.00
|
| Other Expenses |
$1.00 |
$1.38 M |
-$45,690.00 |
$395,401.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$59.67 M |
$57.05 M |
$84.17 M |
$94.05 M |
$61.41 M |
$52.93 M |
$65.01 M |
$22.54 M |
$13.19 M |
$446,892.00 |
| Cost And Expenses |
$59.67 M |
$57.05 M |
$84.17 M |
$94.05 M |
$61.41 M |
$52.93 M |
$65.01 M |
$22.54 M |
$13.19 M |
$446,892.00 |
| Interest Income |
$4.90 M |
$0.00 |
$0.00 |
$395,401.00 |
$948,224.00 |
$952,073.00 |
$201,509.00 |
$0.00 |
$30,281.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$1.60 M
|
$1.38 M
|
$237,000.00
|
$307,000.00
|
$255,000.00
|
$141,733.00
|
$80,310.00
|
$56,512.00
|
$11,778.00
|
$2,315.00
|
| EBITDA |
-$58.71 M
|
-$52.79 M
|
$124.40 M
|
-$81.12 M
|
-$60.21 M
|
-$52.79 M
|
-$64.73 M
|
-$22.48 M
|
-$13.18 M
|
-$444,577.00
|
| EBITDA Ratio |
-149.9 |
-36.96 |
0.6 |
-6.45 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-151.35
|
-36.96
|
0.6
|
-6.45
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$6.94 M
|
$1.38 M
|
-$45,690.00
|
$395,401.00
|
$948,224.00
|
$952,073.00
|
$201,509.00
|
$120,822.00
|
$30,281.00
|
$0.00
|
| Income Before Tax |
-$52.34 M |
-$54.17 M |
$124.16 M |
-$81.04 M |
-$60.46 M |
-$51.98 M |
-$64.81 M |
-$22.41 M |
-$13.16 M |
-$446,892.00 |
| Income Before Tax Ratio
|
-133.62
|
-36.05
|
0.6
|
-6.42
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$2.76 M |
$1.33 M |
-$306,848.00 |
-$1.20 M |
$951,725.00 |
-$80,310.00 |
-$950.00 |
$0.00 |
$0.00 |
| Net Income |
-$52.34 M |
-$51.41 M |
$122.83 M |
-$80.73 M |
-$59.26 M |
-$51.98 M |
-$64.81 M |
-$22.41 M |
-$13.16 M |
-$446,892.00 |
| Net Income Ratio |
-133.62 |
-34.21 |
0.59 |
-6.4 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-0.74 |
-0.73 |
1.78 |
-1.38 |
-1.51 |
-2.11 |
-3.35 |
-1.14 |
-0.67 |
-0.094 |
| EPS Diluted |
-0.74 |
-0.73 |
1.78 |
-1.38 |
-1.51 |
-2.11 |
-3.35 |
-1.14 |
-0.67 |
-0.094 |
| Weighted Average Shares
Out |
$70.58 M
|
$70.42 M
|
$67.48 M
|
$58.45 M
|
$39.22 M
|
$24.63 M
|
$19.34 M
|
$19.60 M
|
$19.60 M
|
$4.75 M
|
| Weighted Average Shares
Out Diluted |
$70.58 M
|
$70.42 M
|
$68.07 M
|
$58.45 M
|
$39.22 M
|
$24.63 M
|
$19.34 M
|
$19.60 M
|
$19.60 M
|
$4.75 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
